Hepatitis C Pricing: Insurers' Cost Benchmarks Would Yield Optimal Price Of $42,000 – Report
This article was originally published in The Pink Sheet Daily
Institute for Clinical and Economic Review reviews how insurers determine when a drug price would require premium increases or coverage restrictions, and suggests $34,000 to $42,000 would be a manageable price range for new hepatitis C treatments based on budget thresholds widely used by payers.
You may also be interested in...
Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.